Yes, GLP-1 receptor agonists can be used in patients on dialysis
Based on the most recent KDIGO 2022 guidelines, GLP-1 receptor agonists are explicitly recommended for patients with type 2 diabetes and chronic kidney disease, including those with eGFR <30 mL/min/1.73 m² or treated with dialysis, when additional glycemic control is needed beyond metformin and SGLT2 inhibitors. 1
Agent Selection and Dosing for Dialysis Patients
The choice of GLP-1 RA matters significantly in this population:
Preferred agents with cardiovascular benefits and data in severe CKD:
- Dulaglutide: Can be used with eGFR >15 mL/min/1.73 m² with no dose adjustment 1
- Liraglutide: No dose adjustment required, though data are limited in severe CKD 1
- Semaglutide (injectable or oral): No dose adjustment required, though data are limited in severe CKD 1
- Lixisenatide: Not recommended with eGFR <15 mL/min/1.73 m² 1
Avoid:
- Exenatide: Use only with CrCl >30 mL/min 1
- Exenatide extended-release: Use only with eGFR >45 mL/min/1.73 m² 1
Clinical Evidence Supporting Use in Dialysis
The most recent and compelling evidence comes from multiple 2026 studies demonstrating real-world benefits:
- Mortality benefit: GLP-1 RA use in incident hemodialysis patients was associated with 17% lower mortality (IRR 0.83,95% CI 0.73-0.95) 2
- Hospitalization reduction: 9% lower hospitalization rate (IRR 0.91,95% CI 0.87-0.96) 2
- Cardiovascular outcomes: 13% lower risk of MACE and 10% lower heart failure hospitalization versus DPP-4 inhibitors 3
- Additional cardiovascular benefits: Reduced myocardial infarction, stroke, and sepsis risk 4
Practical Implementation Algorithm
Starting therapy:
- Begin with dulaglutide 0.75 mg weekly or semaglutide 0.25 mg weekly (best studied in dialysis)
- Titrate slowly over 4-8 weeks to minimize gastrointestinal side effects 1
- Monitor for nausea, vomiting, diarrhea (occurs in 15-20% but usually tolerable) 5
Key monitoring points:
- Watch for volume depletion, especially if combined with loop diuretics
- Reduce insulin or sulfonylurea doses to prevent hypoglycemia 1
- Monitor for gastrointestinal symptoms and adjust dose if severe
- Track dry weight and body composition (expect fat mass reduction without lean tissue loss) 6
Important Caveats
Do not combine with DPP-4 inhibitors - this is explicitly contraindicated 1
The gastrointestinal side effects deserve special attention in dialysis patients. In the real-world semaglutide study, 23% experienced transient nausea that resolved with time or dose adjustment, with no discontinuations required 6. This is manageable with slow titration.
While cardiovascular outcomes trials included patients with eGFR as low as 15 mL/min/1.73 m², dialysis patients were typically excluded from randomized trials 5. However, the 2026 observational data from large cohorts (>3,000 matched dialysis patients) provide robust real-world evidence of benefit 2, 4, 3.
The glycemic efficacy may be reduced compared to non-dialysis patients, but the cardiovascular and mortality benefits appear preserved and may even be enhanced in this high-risk population 5, 2, 4, 3.